Current Options for the Treatment of Urinary Tract Infections Caused by Multiresistant Acinetobacter baumannii

Abstract

Urinary tract infections (UTIs) are the main etiological agent of Gram-negative bacteria. UTI and pneumonia are the main causes of sepsis in older people. With the advance of medicine, the increase in life expectancy, more frequent prescription of immunosuppressive therapies, and indiscriminate use of antibiotics, multidrug-resistant (MDR) pathogens have become a global public health problem. Among them, the rise of MDR Acinetobacter baumannii infections is observed in hospitals, especially in patients accommodated in intensive care units (ICU) and/or in the use of medical devices, such as urinary catheters. Treating UTIs caused by carbapenem-resistant Acinetobacter baumannii became a challenge, given the few therapeutic options and low penetration of polymyxin B into the renal parenchyma.